MiNK Therapeutics ($INKT) Insider Trading & Smart Money Activity

MiNK Therapeutics, Inc. · Biotechnology · Latest filing Oct 12, 2026

MiNK Therapeutics, Inc. ($INKT) has 1 insider trade on file. In the last 12 months on the open market, no insider bought and 1 insider sold ($73.27K), net -$73.27K.

Insider buyers (12 mo): 0
Insider sellers (12 mo): 1
Net insider $ (12 mo): -$73.27K
Congress trades (12 mo): 0
13F moves on file: 0
Analyst ratings on file: 0

INKT insider buying and selling by quarter

Quarter	Insider sales	Congress buys / sales	13F added / cut
Q1 2026	0	0 / 0	0 / 0
Q2 2026	0	0 / 0	0 / 0
Q3 2026	0	0 / 0	0 / 0
Q4 2026	1 · $73.27K	0 / 0	0 / 0

Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.

All INKT insider, congress, 13F and analyst activity

Date	Source	Who	Action	Shares	Value / amount	ΔOwn	1W	1M	6M	Filing	Story
Oct 12, 2026	Insider	Buell JenniferChief Executive Officer	Sell (Open-market sale)	6.94K sh	$73.27K						Read

1W / 1M / 6M = how INKT moved from the trade or filing date.

Insider trading in INKT: who is buying and selling

Insider	Role	Trades	Open-market net	Shares held	Last trade
Buell Jennifer	Chief Executive Officer	1	-$73.27K		Oct 12, 2026

Frequently asked questions

Are INKT insiders buying or selling?

Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 1 insider made 1 open-market sale worth $73.27K, a net -$73.27K.

What is the latest insider trade in INKT?

Buell Jennifer, Chief Executive Officer filed a sell (open-market sale) of 6.94K sh worth $73.27K on Oct 12, 2026.

Other biotechnology stocks

All stocks Insider cluster buys Top insider purchases Congress 13F institutions

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.

Get trade alerts by text